Mike Kelliher - 05 Jan 2026 Form 4 Insider Report for CAPRICOR THERAPEUTICS, INC. (CAPR)

Reporting relationship: Director
Issuer ticker: CAPR
Reported as of: 05 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Jan 2026, 16:45:21 UTC
Prior SEC filing: 25 Nov 2025
Next SEC filing: 26 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Linda Marban, Attorney-in-Fact

Key filing fact

Mike Kelliher filed Form 4 for CAPRICOR THERAPEUTICS, INC. (CAPR) on 07 Jan 2026.

Key facts

This page summarizes Mike Kelliher's Form 4 filing for CAPRICOR THERAPEUTICS, INC. (CAPR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 07 Jan 2026, 16:45.

Change

Previous filing in this sequence was filed on 25 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001987188 Primary reporting owner

Kelliher Mike

Relationship: Director
Address: C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO
Signature: /s/ Linda Marban, Attorney-in-Fact
Signature date: 07 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CAPR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +15,500
Change %
Price: $0.000000
Shares after: 15,500
Date: 05 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,500
Exercise price: $24.81
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares vest 1/12th of the first day of each month, commencing February 1, 2026, with the last month vesting on December 31, 2026, until the stock option becomes fully vested and exercisable. The award pertains to annual board service. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting.